Tulavi Therapeutics
Tulavi Therapeutics is a privately held medical device company that develops the allay Hydrogel Cap, the first FDA-cleared fully absorbable technology to reduce symptomatic neuroma formation, sold to surgeons and hospitals performing peripheral nerve procedures across the U.S.
- Company typePrivate
- Founded2018
- HeadquartersLos Gatos, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tulavi Therapeutics does
Tulavi Therapeutics is a privately held medical device company headquartered in Los Gatos, California that develops the allay™ Hydrogel Cap, the first and only fully absorbable technology FDA-cleared specifically to reduce the risk of symptomatic neuroma formation following peripheral nerve transection. The company was launched in 2018 as a portfolio company of Incept LLC, a hands-on medical technology accelerator that has launched 27 companies over 26 years, and the device is built on Incept's proprietary Adaptive Hydrogel Platform, which has been deployed in over 5 million patients worldwide across multiple specialties.
The allay™ Hydrogel Cap is a fully absorbable, sutureless, in situ forming hydrogel device that conforms to the transected nerve end, creating a non-compressive, hydrophilic barrier that remains in place for approximately 8 months to block axonal escape during the critical period of neuroma formation, after which it hydrolyzes and is absorbed. The product is offered in Small Nerve Set (1-4mm, Model TL-5515-1) and Large Nerve Set (5-7mm, Model TL-5515-2) variants, with single-use delivery tips (Model TL-7627) as an accessory, and the company cites six preclinical studies with n>170 subjects showing no neuroma formation. In October 2025 the FDA indication was expanded to patients weighing 25 kg and above, and in December 2025 the first peer-reviewed clinical data was published in Plastic and Reconstructive Surgery Global Open.
Tulavi monetizes through single-use hardware sales of the allay™ cap to surgeons and hospitals, combining direct enterprise sales with two distribution channels: a January 2026 Vizient Innovative Technology contract providing access to a network representing over $140 billion in annual purchasing volume, and a July 2025 channel partnership with Veterans Healthcare Supply Solutions (VHSS) for VA hospitals and Military Treatment Facilities via the ECAT federal procurement system. The company has raised approximately $5.84 million in disclosed funding across 2018-2021 and is led by CEO Josh Vose (MD, MBA) and Chairman & Co-Founder Fred Khosravi, with board representation from Incept LLC, Delos Capital, and Ascension Ventures.
Tulavi Therapeutics firmographics
Firmographics- Name
- Tulavi Therapeutics
- Legal name
- Tulavi Therapeutics, Inc.
- Website
- https://tulavi.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tulavi Therapeutics is a privately held medical device company that develops the allay Hydrogel Cap, the first FDA-cleared fully absorbable technology to reduce symptomatic neuroma formation, sold to surgeons and hospitals performing peripheral nerve procedures across the U.S.
- Ownership category
- akta.pro rank
Tulavi Therapeutics industry classification
Industry- Product category
- Surgical medical devices — peripheral nerve protection
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)
- akta.pro secondary industry
- Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA)
Keywords
Where Tulavi Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Los Gatos
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Tulavi Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations
Revenue model
- allay™ Hydrogel Cap Sales: Medical device sales model where the allay™ Hydrogel Cap is sold as a single-use surgical device to hospitals, surgeons, and federal healthcare facilities. Revenue generated from product sales through direct sales team, channel partners (VHSS), and GPO contracts (Vizient). Single-use disposable device with per-procedure revenue generation.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Tulavi Therapeutics product offering
Product offeringCore offering
Tulavi Therapeutics develops and commercializes the allay™ Hydrogel Cap, a fully absorbable, sutureless surgical implant designed to protect transected peripheral nerves and reduce the risk of symptomatic neuroma formation. The device forms an in situ hydrogel barrier that conforms to the nerve end, remains in place for approximately eight months, and is sold in small and large nerve size variants to orthopedic and plastic surgeons as well as federal healthcare facilities.
Product overview
Tulavi Therapeutics offers a single core product platform — the allay™ Hydrogel Cap — with specialized configurations for different nerve sizes. The portfolio consists of the main allay™ Hydrogel Cap device (a fully absorbable, sutureless hydrogel barrier for peripheral nerve protection), available in Small Nerve Set (1-4mm, Model TL-5515-1) and Large Nerve Set (5-7mm, Model TL-5515-2) variants, plus Additional Delivery Tips (Model TL-7627) as an accessory. The technology is built on a proprietary Adaptive Hydrogel Platform with demonstrated safety in over 5 million patients worldwide, specifically engineered for nerve healing applications.
Differentiator
Problem solved
Functional benefit
Brands
- allay™ Hydrogel Cap: The first and only fully absorbable technology specifically indicated to reduce the risk of symptomatic neuroma formation. A novel, fully absorbable, sutureless surgical device that provides a perfectly conforming barrier to the injured nerve.
Products and services
- allay™ Hydrogel Cap A fully absorbable, sutureless, in situ forming hydrogel surgical implant designed to protect transected peripheral nerves and reduce the risk of symptomatic neuroma formation. The cap remains in place for approximately 8 months, providing a non-compressive, hydrophilic, flexible barrier that blocks axonal escape during the critical period of neuroma development. Indicated for surgeons performing peripheral nerve procedures in amputations, neuroma excisions, and soft tissue repair.
- allay™ Small Nerve Set (Model # TL-5515-1) Size-specific configuration of the allay™ Hydrogel Cap designed for small peripheral nerves in 1, 2, 3, and 4 mm diameters (Model # TL-5515-1). Enables treatment of multiple smaller nerves across a broad range of sizes in a single procedure.
- allay™ Large Nerve Set (Model # TL-5515-2) Size-specific configuration of the allay™ Hydrogel Cap designed for larger peripheral nerves in 5, 6, and 7 mm diameters (Model # TL-5515-2). Enables treatment of multiple larger nerves across a broad range of sizes in a single procedure.
- allay™ Additional Delivery Tips (Model # TL-7627) Single-use delivery tips for the allay™ Hydrogel Cap system, sold as a separately packaged accessory (Model # TL-7627). One box contains six packages, each with one single-use delivery tip.
Quantifiable outcome
- No neuroma formation demonstrated across 6 preclinical studies with n>170 subjects
- +3 more outcomes
Companies that use Tulavi Therapeutics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Tulavi Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Tulavi Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- VizientcoreInnovative Technology contract awarded to allay™ Hydrogel Cap. Vizient is the nation's largest provider-driven healthcare performance improvement company representing over $140 billion in annual purchasing volume. The contract signifies unique qualities that potentially bring improvement to healthcare and enables access to Vizient's diverse client base including academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers.
- Veterans Healthcare Supply Solutions (VHSS)corePartnership to distribute the allay™ Hydrogel Cap to U.S. Department of Veterans Affairs (VA) hospitals and Military Treatment Facilities nationwide. This partnership brings Tulavi's innovative technology to the forefront of veteran care, expanding access to treatment for peripheral nerve injuries. The allay™ Hydrogel Cap is now available to federal healthcare providers via the ECAT through VHSS.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Tulavi Therapeutics competitors and assessment
Company assessmentDirect peers
- Axogen: Market-leading peripheral nerve repair company with the Avance nerve allograft platform, dominating the same surgical specialty (peripheral nerve surgeons performing neuroma management, amputation, and nerve gap procedures) that Tulavi targets with allay™.
- Cook Medical: Manufactures nerve repair and surgical devices including nerve conduits, supplying the same peripheral nerve surgeon specialty with overlapping neuroma management solutions.
Emerging players
- Renerve: Early-stage company developing nerve regeneration and neuroma prevention technologies targeting the same peripheral nerve surgery market as Tulavi's allay™ Hydrogel Cap.
- Polyganics: Develops NEUROCAP, a biodegradable nerve cap device for symptomatic neuroma prevention — a directly comparable product concept to Tulavi's allay™ Hydrogel Cap, competing for the same surgical indication and customer base.
Broad incumbents
- Baxter International: Through its surgical solutions portfolio (including legacy Synovis Micro Companies Alliance products), Baxter competes in the peripheral nerve repair and microsurgery space served by Tulavi.
- RTI Surgical: Medical device company offering surgical implants including nerve repair solutions that compete for the same hospital procurement budgets in peripheral nerve procedures.
- Integra LifeSciences: Large diversified medical device company with a peripheral nerve repair portfolio including NeuraGen nerve guide and related products, serving overlapping surgical customers across reconstructive and orthopedic surgery.
- Stryker: Major medical device incumbent with broad surgical and orthopedic portfolios that compete for the same hospital budgets and OR shelf space as Tulavi's allay™ product.
- Medtronic: Global medical device leader with neurostimulation and surgical portfolios that overlap the peripheral nerve treatment space and compete for hospital formulary inclusion in the same accounts Tulavi targets.
Others
- Collagen Solutions: Supplier of collagen-based biomaterials used in nerve repair devices and surgical applications, adjacent to Tulavi's hydrogel platform as an enabling technology provider in the same surgical ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Tulavi Therapeutics social profiles
Digital presenceTulavi Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tulavi Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Tulavi Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tulavi Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tulavi Therapeutics
What does Tulavi Therapeutics do?
Tulavi Therapeutics develops and commercializes the allay™ Hydrogel Cap, a fully absorbable, sutureless surgical implant designed to protect transected peripheral nerves and reduce the risk of symptomatic neuroma formation. The device forms an in situ hydrogel barrier that conforms to the nerve end, remains in place for approximately eight months, and is sold in small and large nerve size variants to orthopedic and plastic surgeons as well as federal healthcare facilities.
Is Tulavi Therapeutics a public or private company?
Tulavi Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Tulavi Therapeutics founded?
Tulavi Therapeutics was founded in 2018. It employs 11 to 50 people.
Where is Tulavi Therapeutics based?
Tulavi Therapeutics is headquartered in Los Gatos, United States, in the North America region.
How does Tulavi Therapeutics make money?
One revenue line is on record: allay™ Hydrogel Cap Sales.
Who are Tulavi Therapeutics's main competitors?
Direct peers on record are Axogen and Cook Medical. Emerging players are Renerve and Polyganics. Broad incumbents are Baxter International, RTI Surgical, Integra LifeSciences, Stryker and Medtronic. Collagen Solutions is listed as an others.
Does Tulavi Therapeutics have an API?
No public API is recorded for Tulavi Therapeutics.
What industry is Tulavi Therapeutics in?
Tulavi Therapeutics's product category is Surgical medical devices — peripheral nerve protection. Its primary akta.pro industry code is HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 339113 and its SIC code is 3841.